Prohibiting payment to residential substance use disorder treatment facilities that do not meet certain requirements
Summary
SB 867 would change West Virginia law governing Medicaid reimbursement for residential substance use disorder treatment facilities. The bill requires the Bureau for Medical Services, and any managed care organization acting for it, to stop paying for residential SUD treatment services unless the facility is both licensed by the state Office of Health Facility Licensure and Certification and accredited by one of three recognized accrediting bodies: CARF, The Joint Commission, or DNV. The bill also requires the Bureau to make the necessary federal filings and update provider manuals so the reimbursement restrictions can be enforced.
The bill accelerates the compliance timeline for facilities, moving the operative date from January 1, 2026 to July 1, 2025 in the text as introduced, and requiring new or relocated facilities to meet accreditation requirements within one year of starting operations while still complying with state licensure and other reimbursement rules during that period. It also directs the Office of the Inspector General to promulgate implementing rules, requires a report to the Legislative Oversight Commission on Health and Human Resources Accountability by December 31, 2030, and sunsets the section on July 1, 2031 unless reenacted.
Impact
The bill would amend and reenact West Virginia Code §9-5-29a, tightening the conditions under which Medicaid and managed care plans may reimburse residential substance use disorder treatment providers. In practical terms, it would affect the Bureau for Medical Services, Medicaid managed care organizations, and residential SUD treatment facilities by making licensure and national accreditation prerequisites for payment. It also interacts with existing state health facility licensing and substance abuse treatment bed requirements, and it requires administrative rulemaking and federal Medicaid-related filings to implement the change.
Sentiment
The available context suggests the bill is framed as a regulatory and quality-control measure rather than a controversial policy expansion, with the stated purpose of ensuring facilities meet licensure and accreditation standards sooner. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the supplied materials. The caption and bill text indicate a generally enforcement-oriented approach focused on compliance and reimbursement standards.
Contention
The main point of potential contention is the accelerated compliance deadline, which could be difficult for some residential substance use disorder treatment facilities to meet, especially newer providers or those operating on thin margins. Facilities may also object to the cost and administrative burden of obtaining accreditation from CARF, The Joint Commission, or DNV in order to remain eligible for reimbursement. On the other hand, supporters would likely emphasize patient safety, treatment quality, and the need to ensure public funds only support fully licensed and accredited providers. The bill also places implementation responsibility on the Bureau for Medical Services and the Office of the Inspector General, which may raise administrative concerns about timing and rulemaking.